Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis

FEBS Journal

Volumn , Issue , 2016, Pages 3438-3456

  Ha, Danbee ^a   Bing, So Jin ^a   Ahn, Ginnae ^b   Kim, Jinhee ^a   Cho, Jinhee ^a   Kim, Areum ^a   Herath, Kalahe H I N M ^a   Yu, Hak Sun ^c   Jo, Sangmee Ahn ^d   Cho, Ik Hyun ^e   Jee, Youngheun ^a  

^a Jeju National University   (South Korea)

^b Chonnam National University   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Dankook University   (South Korea)

^e Kyung Hee University   (South Korea)

Author keywords

2 phosphonomethyl pentanedioic acid; experimental autoimmune encephalomyelitis (EAE); glutamate carboxypeptidase II; glutamate excitotoxicity; metabotropic glutamate receptors

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMIC ACID; METABOTROPIC RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; ENZYME INHIBITION; EXCITOTOXICITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOREGULATION; INFLAMMATORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TH1 CELL;

EID: 84987936728     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13816     Document Type: Article

References (39)

1. Baxter AG (2007) The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 7, 904–912.
2. Pitt D, Werner P & Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6, 67–70.
3. Fallarino F, Volpi C, Fazio F, Notartomaso S, Vacca C, Busceti C, Bicciato S, Battaglia G, Bruno V, Puccetti P et al. (2010) Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med 16, 897–902.
4. Hansen AM & Caspi RR (2010) Glutamate joins the ranks of immunomodulators. Nat Med 16, 856–858.
5. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J & Hilgenfeld R (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 25, 1375–1384.
6. Robinson MB, Blakely RD, Couto R & Coyle JT (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 262, 14498–14506.
7. Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ et al. (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA 100, 9554–9559.
8. Kang KA, Zhang R, Chae S, Lee SJ, Kim J, Kim J, Jeong J, Lee J, Shin T, Lee NH et al. (2010) Phloroglucinol (1,3,5-trihydroxybenzene) protects against ionizing radiation-induced cell damage through inhibition of oxidative stress in vitro and in vivo. Chem Biol Interact 185, 215–226.
9. Zhou J, Neale JH, Pomper MG & Kozikowski AP (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 4, 1015–1026.
10. Berger UV, Luthi-Carter R, Passani LA, Elkabes S, Black I, Konradi C & Coyle JT (1999) Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J Comp Neurol 415, 52–64.
11. Werner P, Pitt D & Raine CS (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50, 169–180.
12. Yamamoto T, Saito O, Aoe T, Bartolozzi A, Sarva J, Zhou J, Kozikowski A, Wroblewska B, Bzdega T & Neale JH (2007) Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur J Neurosci 25, 147–158.
13. Luthi-Carter R, Berger UV, Barczak AK, Enna M & Coyle JT (1998) Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci USA 95, 3215–3220.
14. Stinissen P, Medaer R & Raus J (1998) Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis. Mult Scler 4, 203–211.
15. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D et al. (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899–911.
16. Pacheco R, Ciruela F, Casadó V, Mallol J, Gallart T, Lluis C & Franco R (2004) Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J Biol Chem 279, 33352–33358.
17. Geurts JJG, Wolswijk G, Bö L, van der Valk P, Polman CH, Troost D & Aronica E (2003) Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain J Neurol 126, 1755–1766.
18. Brück W (2005) Clinical implications of neuropathological findings in multiple sclerosis. J Neurol 252 (Suppl 3), iii10–iii14.
19. Bauer J, Huitinga I, Zhao W, Lassmann H, Hickey WF & Dijkstra CD (1995) The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 15, 437–446.
20. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G & Martino G (2010) The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ 17, 1083–1091.
21. Neale JH (2011) N-acetylaspartylglutamate (NAAG) is an agonist at mGluR3 in vivo and in vitro. J Neurochem 119, 891–895.
22. Sanabria ERG, Wozniak KM, Slusher BS & Keller A (2004) GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J Neurophysiol 91, 182–193.
23. Xi Z-X, Li X, Peng X-Q, Li J, Chun L, Gardner EL, Thomas AG, Slusher BS & Ashby CR (2010) Inhibition of N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem 112, 564–576.
24. Nakanishi S (1992) Molecular diversity of glutamate receptors and implications for brain function. Science 258, 597–603.
25. Bolton C & Paul C (2006) Glutamate receptors in neuroinflammatory demyelinating disease. Mediators Inflamm 2006, 93684.
26. Besong G, Battaglia G, D'Onofrio M, Di Marco R, Ngomba RT, Storto M, Castiglione M, Mangano K, Busceti CL, Nicoletti FR et al. (2002) Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J Neurosci 22, 5403–5411.
27. Pacheco R, Gallart T, Lluis C & Franco R (2007) Role of glutamate on T-cell mediated immunity. J Neuroimmunol 185, 9–19.
28. Pacheco R, Oliva H, Martinez-Navío JM, Climent N, Ciruela F, Gatell JM, Gallart T, Mallol J, Lluis C and Franco R (2006) Glutamate released by dendritic cells as a novel modulator of T cell activation. J Immunol 177, 6695–6704.
29. Rais R, Rojas C, Wozniak K, Wu Y, Zhao M, Tsukamoto T, Rudek MA & Slusher BS (2014) Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA). J Pharm Biomed Anal 88, 162–169.
30. Puentes F, Dickhaut K, Hofstätter M, Falk K & Rötzschke O (2013) Active suppression induced by repetitive self-epitopes protects against EAE development. PLoS One 8, e64888.
31. Ohmori K, Hong Y, Fujiwara M & Matsumoto Y (1992) In situ demonstration of proliferating cells in the rat central nervous system during experimental autoimmune encephalomyelitis. Evidence suggesting that most infiltrating T cells do not proliferate in the target organ. Lab Invest 66, 54–62.
32. Liu X, Ciumas C, Huang Y-M, Steffensen KR, Lian H, Link H & Xiao B-G (2005) Autoantigen-pulsed dendritic cells constitute a beneficial cytokine and growth factor network in ameliorating experimental allergic encephalomyelitis. Mult Scler 11, 381–389.
33. Kim M-J, Chae SS, Koh YH, Lee SK & Jo SA (2010) Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain. FASEB J 24, 4491–4502.
34. Sakuma H, Kohyama K, Park I-K, Miyakoshi A, Tanuma N & Matsumoto Y (2004) Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats. Brain J Neurol 127, 2201–2213.
35. Jee Y, Piao WH, Liu R, Bai XF, Rhodes S, Rodebaugh R, Campagnolo DI, Shi FD & Vollmer TL (2007) CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol 125, 34–42.
36. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S et al. (2008) Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111, 715–722.
37. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD & Song W-C (2005) The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201, 567–577.
38. Noorbakhsh F, Tsutsui S, Vergnolle N, Boven LA, Shariat N, Vodjgani M, Warren KG, Andrade-Gordon P, Hollenberg MD & Power C (2006) Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 203, 425–435.
39. Nataf S, Carroll SL, Wetsel RA, Szalai AJ and Barnum SR (2000) Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol 165, 5867–5873.